When was Cleara founded?

Cleara was founded in 2017 and raised its 1st funding round 2 years after it was founded.

Where is Cleara located?

Cleara is headquartered in Utrecht, Netherlands.

How many employees does Cleara have?

As of Aug 31, 2026, the latest employee count at Cleara is 10.

Is Cleara a funded company?

Cleara is a funded company, having raised a total of $2.5M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2019.

When was the latest funding round of Cleara?

Cleara's latest funding was a $***** Seed round on Sep 28, 2022, with participation from 4 investors. Its primary sector is Life Sciences Platforms and Tools. Globally, the Life Sciences Platforms and Tools sector has seen $2.61B in funding in 2026 to date.

Where does Cleara rank among its competitors?

Cleara ranks 305th amongst 2307 active competitors, of which 547 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of Cleara?

Cleara's top competitors include Abcellera Biologics, Agios Pharmaceuticals and TScan Therapeutics. Among them, Antheia secured the most recent funding round in January, 2026.

Cleara - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of biomarkers and therapies to treat cancer and aging diseases. The company has discovered a protein biomarker, FOXO4 targeting FOXO4 proteins (neutralizing Doxorubicin-induced chemotoxicity) to inhibit and induce apoptosis in senescent cells via P53 genes.

Website: www.clearabiotech.com/
Social

Key Metrics

Founded Year

2017

Location

Utrecht, Netherlands

Stage

Seed

Total Funding

$2.5M in 2 rounds

Latest Funding Round

Seed, Sep 28, 2022, $*****

Investors

FJ Labs & 6 more

Ranked

305^th among 2307 active competitors

Employee Count

10 as on Aug 31, 2026

Similar Companies

Abcellera Biologics & 3091 more

View Cleara's full profile

Cleara has raised a total funding of $2.5M over 2 rounds. Its first funding round was on 2019. Its latest funding round was a Seed round on Sep 28, 2022 for $*****. 4 investors participated in its latest round. Cleara has 7 institutional investors.

Here is the list of recent funding rounds of Cleara:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 28, 2022	5367478	Seed	2588986	7651326	6648547	8852468
2019	9370	Seed	1457	2858	FJ Labs	8483

Access funding benchmarks and valuations. Sign up today!

View details of Cleara's funding rounds and investors

The founders of Cleara are Peter and Marco Demaria.

Here are the details of Cleara's key team members:

Peter: Co-Founder & MD of Cleara.
Contact Info: 1 email address
Marco Demaria: Co-Founder of Cleara.

View details of Cleara's Founder profiles and Board Members

Cleara's employee count trend

Cleara has 10 employees as of Aug 26. Here is Cleara's employee count trend over the years:

Uncover Cleara's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cleara include Abcellera Biologics, Agios Pharmaceuticals and TScan Therapeutics. Here is the list of Top 10 competitors of Cleara, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
2nd	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
3rd	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	RA Capital Management, Novartis & 9 others	70/100
4th	Beijing Jiakesi drug development 2015, Beijing (China), Public	Developer of small molecule based therapeutics for cancer treatment	$55M	Qiming Venture Partners, Lilly Asia Ventures ... & 3 others	67/100
5th	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
6th	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
7th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
8th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 14 others	64/100
9th	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	64/100
10th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
305th	Cleara 2017, Utrecht (Netherlands), Seed	Developer of biomarkers and therapies to treat cancer and aging diseases	$2.5M	TruVenturo, FJ Labs & 5 others	42/100